S&P Futures
3,862.25 +14.00 (+0.36%) Dow Futures
31,118.00 +105.00 (+0.34%) Nasdaq Futures
11,943.25 +63.00 (+0.53%) Russell 2000 Futures
1,736.60 +8.00 (+0.46%) Crude Oil
98.88 +0.35 (+0.36%) Gold
1,742.00 +5.50 (+0.32%)
AVEO Pharmaceuticals, Inc. (AVEO)
After hours:
Chart Events
Performance Outlook
| Previous Close | 7.00 |
| Open | 6.93 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 1000 |
| Day's Range | 7.00 - 7.25 |
| 52 Week Range | 3.06 - 7.55 |
| Volume | |
| Avg. Volume | 227,485 |
| Market Cap | 246.462M |
| Beta (5Y Monthly) | 1.16 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.88 |
| Earnings Date | Mar 14, 2022 - Mar 18, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.40 |
- Simply Wall St.
Strong week for AVEO Pharmaceuticals (NASDAQ:AVEO) shareholders doesn't alleviate pain of five-year loss
This week we saw the AVEO Pharmaceuticals, Inc. ( NASDAQ:AVEO ) share price climb by 20%. But will that heal all the...
- GlobeNewswire
AVEO Oncology Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company for ERBITUX® (cetuximab) in North America to Evaluate Ficlatuzumab and Cetuximab in Patients with Recurrent or Metastatic HNSCC
- This agreement follows AVEO’s entry into a similar agreement with Merck KGaA, Darmstadt, Germany to provide cetuximab clinical drug supply outside of the U.S. and Canada - - AVEO Currently Manufacturing Ficlatuzumab Clinical Supply; Potential Phase 3 Registrational Clinical Trial in HPV Negative R/M HNSCC Expected in 1H 2023 - BOSTON, June 22, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it has enter
- GlobeNewswire
AVEO Oncology Announces Updated NCCN Clinical Practice Guidelines Elevate FOTIVDA® (tivozanib) to Category 1 Treatment for Relapsed or Refractory Advanced (R/R) Renal Cell Carcinoma (RCC) Patients
BOSTON, June 21, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced the National Comprehensive Cancer Network® (NCCN) has elevated FOTIVDA® (tivozanib) to Category 1 status as a subsequent therapy for RCC patients who have received two or more prior therapies in the latest Kidney Cancer Treatment Guidelines released on June 17, 2022. “Category 1 is the highest Category recommendation offered by NCCN, which is bas
